Antonio Almeida is currently head of department at Hospital da Luz, Lisbon, Portugal and also head of the hemato-oncology diagnostic laboratory at the Portuguese Institute of Oncology in Lisbon.

He was awarded his medical degree in 1993 from Cambridge University, UK, and completed his Specialist Training in Haematology in the UK in 2002. Following this Dr Almeida completed a clinical research fellowship through the Leukaemia Research Fund at Imperial College, London, and was awarded a PhD in 2007 for his work on the molecular characterization and targeted therapy for Inherited GPI Deficiency.

Dr Almeida’s research interests include myeloproliferative and myelodysplastic syndromes, focusing on epigenetic regulation of transcription regulation. He leads a Haematology Epigenetic research group and is the national principal investigator for several clinical trials in CML and MDS.

Dr Almeida has written book chapters and is the author of a range of articles published in journals including New England Journal of Medicine, Nature Medicine and Blood.

Paper

Acute myeloid leukemia in the older adults

Almeida, A. , Almeida, A.M.. (2016). Acute myeloid leukemia in the older adults. Leukemia Research Reports
Paper

Automated computer result reporting for haemoglobinopathy screening

Almeida, A. , Daniel, Y.. (2004). Automated computer result reporting for haemoglobinopathy screening. Clinical and Laboratory Haematology
Paper

Bone involvement in sickle cell disease

Almeida, A. , Almeida, A.. (2005). Bone involvement in sickle cell disease. British Journal of Haematology
Paper

Cell-type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiency

Almeida, A. , Costa, J.R.. (2014). Cell-type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiency. Blood
Paper

Chapter 16 Inherited GPI deficiency

Almeida, A. , Almeida, A.. (2009). Chapter 16 Inherited GPI deficiency. Enzymes
Paper

Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry

Almeida, A. , Almeida, A.M.. (2017). Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Internal Medicine Journal
Paper

Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial

Almeida, A. , Guillermo Garcia-Manero. (2019). Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial. Clinical Lymphoma Myeloma and Leukemia
Paper

Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

Almeida, A. , Nolte, F.. (2011). Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leukemia Research
Paper

Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

Almeida, A. , Almeida, A.M.. (2017). Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study. International Journal of Molecular Sciences
Paper

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study

Almeida, A. , Almeida, A.. (2017). Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study. Leukemia Research Reports
Paper

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective

Almeida, A. , Giuseppe Saglio. (2018). Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective. Clinical Lymphoma Myeloma and Leukemia
Paper

Design and rationale of the QUAZAR lower-risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes a...

Almeida, A. , Garcia-Manero, G.. (2016). Design and rationale of the QUAZAR lower-risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes a.... BMC Hematology
Paper

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Almeida, A. , Roboz, G.J.. (2016). Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncology
Paper

Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients

Almeida, A. , Urbano-Ispizua, Á.. (2017). Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. Haematologica
Paper

Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS

Almeida, A. , Pierdomenico, F.. (2013). Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS. Annals of Hematology
Paper

Epigenetic Alterations in Fanconi anaemia: Role in pathophysiology and therapeutic potential

Almeida, A. , Belo, H.. (2015). Epigenetic Alterations in Fanconi anaemia: Role in pathophysiology and therapeutic potential. PLoS ONE
Paper

Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation

Almeida, A. , McCloy, M.. (2001). Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation. British Journal of Haematology
Paper

Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone

Almeida, A. , Almeida, A.M.. (2012). Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone. Leukemia Research
Paper

HDAC8 overexpression in mesenchymal stromal cells from JAK2<sup>+</sup>myeloproliferative neoplasms: A new therapeutic target?

Almeida, A. , Ramos, T.L.. (2017). HDAC8 overexpression in mesenchymal stromal cells from JAK2+myeloproliferative neoplasms: A new therapeutic target?. Oncotarget
Paper

Hematology traning in Europe

Almeida, A. , A. Almeida. (2018). Hematology traning in Europe. International Journal of Laboratory Hematology
Paper

Human invariant NKT cells are required for effective in vitro alloresponses

Almeida, A. , Patterson, S.. (2005). Human invariant NKT cells are required for effective in vitro alloresponses. Journal of Immunology
Paper

Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency

Almeida, A. , Almeida, A.M.. (2006). Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency. Nature Medicine
Paper

Inherited glycosylphosphatidyl inositol deficiency: A treatable CDG

Almeida, A. , Almeida, A.. (2009). Inherited glycosylphosphatidyl inositol deficiency: A treatable CDG. Biochimica et Biophysica Acta - Molecular Basis of Disease
Paper

Modifying disease in CMML: Who responds to Azacitidine?

Almeida, A. , Almeida, A.. (2013). Modifying disease in CMML: Who responds to Azacitidine?. Leukemia Research
Paper

Neonatal screening for haemoglobinopathies: The results of a 10-year programme in an English Health Region

Almeida, A. , Almeida, A.M.. (2001). Neonatal screening for haemoglobinopathies: The results of a 10-year programme in an English Health Region. British Journal of Haematology
Paper

Neonatal screening for sickle cell disorders

Almeida, A. , Henthorn, J.S.. (2004). Neonatal screening for sickle cell disorders. British Journal of Haematology
Paper

Optimizing treatments in rare diseases: Will our evidence come from registry data?

Almeida, A. , Almeida, A.M.. (2014). Optimizing treatments in rare diseases: Will our evidence come from registry data?. Leukemia Research
Paper

Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents

Almeida, A. , Santini, V.. (2016). Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. Journal of Clinical Oncology
Paper

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)

Almeida, A. , Falantes, J.. (2017). Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). Leukemia and Lymphoma
Paper

Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

Almeida, A. , Almeida, A.. (2017). Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leukemia Research
Paper

Recommendations for diagnosis, treatment and monitoring of chronic myeloid leukemia | Recomendações para o diagnóstico, tratamento e monitorização da leucemia mielóide crónica

Almeida, A. , Almeida, A.. (2009). Recommendations for diagnosis, treatment and monitoring of chronic myeloid leukemia | Recomendações para o diagnóstico, tratamento e monitorização da leucemia mielóide crónica. Acta Medica Portuguesa
Paper

Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells

Almeida, A. , Kotsianidis, I.. (2006). Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood
Paper

Should more MDS patients be treated with immune-suppression?

Almeida, A. , Antonio Almeida. (2018). Should more MDS patients be treated with immune-suppression?. Leukemia Research
Paper

Targeted therapy for inherited GPI deficiency

Almeida, A. , Almeida, A.M.. (2007). Targeted therapy for inherited GPI deficiency. New England Journal of Medicine
Paper

The bone marrow-mediated protection of myeloproliferative neoplastic cells to vorinostat and ruxolitinib relies on the activation of JNK and PI3K Signalling Pathways

Almeida, A. , Cardoso, B.A.. (2015). The bone marrow-mediated protection of myeloproliferative neoplastic cells to vorinostat and ruxolitinib relies on the activation of JNK and PI3K Signalling Pathways. PLoS ONE
Paper

The use of recombinant factor VIIa in children with inherited platelet function disorders

Almeida, A. , Almeida, A.M.. (2003). The use of recombinant factor VIIa in children with inherited platelet function disorders. British Journal of Haematology
Paper

Therapeutic challenges in childhood sickle cell disease Part 1: Current and future treatment options

Almeida, A. , Amrolia, P.J.. (2003). Therapeutic challenges in childhood sickle cell disease Part 1: Current and future treatment options. British Journal of Haematology
Paper

Therapeutic challenges in childhood sickle cell disease. Part 2: A problem-orientated approach

Almeida, A. , Amrolia, P.J.. (2003). Therapeutic challenges in childhood sickle cell disease. Part 2: A problem-orientated approach. British Journal of Haematology
Paper

Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.

Almeida, A. , Hunt, B.J.. (2003). Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Paper

Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.

Almeida, A. , Hunt, B.J.. (2003). Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Paper

Treatment of acute erythroleukemia with Azacitidine: A case series

Almeida, A. , Pierdomenico, F.. (2013). Treatment of acute erythroleukemia with Azacitidine: A case series. Leukemia Research Reports
Paper

Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review

Almeida, A. , Thorpe, M.. (2012). Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review. Leukemia Research
Paper

Unusual presentation of factor XIII deficiency

Almeida, A. , Almeida, A.. (2002). Unusual presentation of factor XIII deficiency. Haemophilia
Paper

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

Almeida, A. , de Swart, L.. (2015). Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. British Journal of Haematology
Paper

Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms

Almeida, A. , Silva, G.. (2013). Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms. PLoS ONE
Paper

Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms

Almeida, A. , Bruno A. Cardoso. (2019). Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms. Experimental Hematology